CDKN2A and neoplasm: There may exist relatively small subcohorts of WHO grade 1 and 2 meningioma patients exhibiting heterozygous CDKN2A/B deletions, and these cases might be currently underestimated in terms of postoperative risk stratification for tumor progression.